Analysis of the significantly different metabolomic features. حسب Bhuripit Saraphol (20855573)

الموضوعات:

Correlations between significantly different microbiota and metabolites. حسب Bhuripit Saraphol (20855573)

الموضوعات:

The top 10 putative metabolites with the largest negative fold change between normal and thin cows. حسب Bhuripit Saraphol (20855573)

الموضوعات:

The top 10 putative metabolites with the largest positive fold change between normal and thin cows. حسب Bhuripit Saraphol (20855573)

الموضوعات:

Box plots showing the taxa that were significantly different between thin and normal cows. حسب Bhuripit Saraphol (20855573)

الموضوعات:

DataSheet1_The OsGAPC3 mutation significantly affects grain quality traits and improves the nutritional quality of rice.docx حسب Bo Peng (273834)

"…Additionally, the OsGAPC3 mutation significantly decreases the rice-seedling salt tolerance. …"

Socio-demographic and medical characteristics of patients with liver cancer. حسب Ayana Ablayeva (22103708)

الموضوعات:

Data cleaning and preparation algorithm. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. حسب Ayana Ablayeva (22103708)

الموضوعات:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. حسب Ayana Ablayeva (22103708)

الموضوعات:

Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). حسب Ayana Ablayeva (22103708)

الموضوعات:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. حسب Claire M. Douglas (21238238)

الموضوعات: